Elanco Animal Health (ELAN)
NYSE:ELAN
Want to see ELAN full AI Analyst Report?
ELAN Stock Chart & Stats
$23.68
-$0.30(-2.54%)
At close: 4:00 PM EST
$23.68
-$0.30(-2.54%)
Day’s Range― - ―
52-Week Range$13.16 - $27.72
Previous CloseN/A
Volume2.53M
Average Volume (3M)6.74M
Market Cap
$11.80B
Enterprise Value$15.48B
Total Cash (Recent Filing)$428.00M
Total Debt (Recent Filing)$3.99B
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Aug 10, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding499,449,600
10 Day Avg. Volume6,936,197
30 Day Avg. Volume6,737,090
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)1.72
Price to Sales (P/S)2.38
P/FCF Ratio39.55
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit6.40
Enterprise Value/Ebitda20.51
Forecast
1Y Price Target
$29.17Price Target Upside23.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)1.06
Revenue Forecast (FY)$5.06B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationSustained positive free cash flow despite accounting losses indicates the core business generates real cash to fund operations, launches and debt paydown. Durable cash generation reduces refinancing risk, supports the company’s deleveraging path and finances productivity programs without relying on external capital.
Blockbuster New-product AdoptionRapid clinic penetration, high reorder rates and multi-market uptake signal sticky demand and strong competitive positioning for key innovations. Durable adoption of new branded products supports sustainable top-line growth, pricing power and margin expansion as lifecycle sales scale globally.
Improving Leverage And Capital StructureA sizable equity base and a clear deleveraging roadmap provide balance-sheet flexibility. Management’s targeted leverage reduction and >$1B free cash flow goal through 2028 create a credible medium-term path to lower financial risk and enable strategic reinvestment or M&A when execution is proven.
Bears Say
Uneven ProfitabilityPersistent negative net margins and episodic profitability reduce predictability of returns and weaken long-term ROE. Volatility in earnings complicates capital allocation, may constrain dividends or buybacks, and raises the bar for sustaining improvement through margin or volume gains.
Regulatory & Capacity Risk (Zenrelia)Regulatory delays and additional study requirements can postpone U.S. label expansion and full commercial upside, while 24/7 capacity scaling increases execution and capital risk. These structural hurdles could slow realization of product potential and pressure near-to-medium term cash conversion.
Gross Margin PressureInventory cost flow‑through, inflation and mix effects compress gross margins and limit profit leverage from revenue growth. If margin recovery is delayed, it will slow EBITDA conversion, hinder deleveraging targets and reduce the durability of margin improvements from operational initiatives.
Elanco Animal Health News
ELAN FAQ
What was Elanco Animal Health’s price range in the past 12 months?
Elanco Animal Health lowest stock price was $13.15 and its highest was $27.72 in the past 12 months.
What is Elanco Animal Health’s market cap?
Elanco Animal Health’s market cap is $11.80B.
When is Elanco Animal Health’s upcoming earnings report date?
Elanco Animal Health’s upcoming earnings report date is Aug 10, 2026 which is in 66 days.
How were Elanco Animal Health’s earnings last quarter?
Elanco Animal Health released its earnings results on May 06, 2026. The company reported $0.4 earnings per share for the quarter, beating the consensus estimate of $0.346 by $0.054.
Is Elanco Animal Health overvalued?
According to Wall Street analysts Elanco Animal Health’s price is currently Undervalued.
Does Elanco Animal Health pay dividends?
Elanco Animal Health does not currently pay dividends.
What is Elanco Animal Health’s EPS estimate?
Elanco Animal Health’s EPS estimate is 0.27.
How many shares outstanding does Elanco Animal Health have?
Elanco Animal Health has 499,449,600 shares outstanding.
What happened to Elanco Animal Health’s price movement after its last earnings report?
Elanco Animal Health reported an EPS of $0.4 in its last earnings report, beating expectations of $0.346. Following the earnings report the stock price went up 13.876%.
Which hedge fund is a major shareholder of Elanco Animal Health?
Currently, no hedge funds are holding shares in ELAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elanco Animal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.17 (23.17% Upside)
$29.17 (23.17% Upside)
Blogger Sentiment
Bullish
ELAN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 11.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $199.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.54%
12-Months-Change
Fundamentals
Return on Equity
-3.64%
Trailing 12-Months
Asset Growth
2.17%
Trailing 12-Months
Company Description
Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
ELAN Company Deck
ELAN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a materially positive picture: strong Q1 performance (10% organic growth, $1.371B revenue), major share gains and product momentum (Zenrelia, Credelio Quattro and Adtab), raised full-year guidance, meaningful EBITDA and EPS improvement, and a credible path to deleveraging supported by Elanco Ascend productivity plans and disciplined M&A. Near-term headwinds include a 40-basis-point gross margin decline in Q1, higher operating investments, regulatory work required for Zenrelia's U.S. label expansion, capacity scaling needs, and external timing effects (China/Middle East) and competitive risks that could temper near-term upside. Overall, the positives (outperformance, raised guidance, blockbuster product traction and clear balance-sheet focus) outweigh the manageable operational and timing risks discussed.View all ELAN earnings summariesELAN Stock 12 Month Forecast
Average Price Target
$29.17
▲(23.17% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Teva Pharmaceutical
―
Zoetis
―
Phibro Animal Health
―
Ownership Overview
0.97% Insiders
51.95% Mutual Funds
18.46% Other Institutional Investors
7.19% Public Companies and
Individual Investors